Search our Database of Scientific Publications and Authors

I’m looking for a

    1042 results match your criteria American Journal of Clinical Dermatology[Journal]

    1 OF 21

    Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.
    Am J Clin Dermatol 2018 Feb 16. Epub 2018 Feb 16.
    Mount Sinai St. Luke's, 1090 Amsterdam Avenue, Suite 11B, New York, NY, 10025, USA.
    In the original publication, section 5, paragraph 1 was incorrectly published. Read More

    Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.
    Am J Clin Dermatol 2018 Feb 7. Epub 2018 Feb 7.
    Department of Dermatology, Medical Faculty of Technische Universität Dresden, University Hospital Carl Gustav Carus, University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
    Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint inhibitors are active in patients with melanoma brain metastases (MBM), reporting intracranial disease control rates of 50-75%. Furthermore, retrospective analyses suggest that combining stereotactic radiosurgery with immune checkpoint inhibitors or BRAF/MEK inhibitors prolongs overall survival. These data stress the need for inter- and multidisciplinary cooperation that takes into account the individual prognostic factors in order to establish the best treatment for each patient. Read More

    A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea.
    Am J Clin Dermatol 2018 Feb 2. Epub 2018 Feb 2.
    Foamix Pharmaceuticals, Ltd, 2 Holzman Street, Weizmann-Science Park, 7670402, Rehovot, Israel.
    Objective: Our objective was to demonstrate the safety, tolerability, and efficacy of a minocycline foam, FMX103, in the treatment of moderate-to-severe facial papulopustular rosacea.

    Methods: This was a phase II, randomized, double-blind, multicenter study. Healthy subjects aged ≥ 18 years with moderate-to-severe rosacea that had been diagnosed ≥ 6 months previously and with ≥ 12 inflammatory facial lesions were randomized (1:1:1) to receive once-daily 1. Read More

    Treatment of Autoimmune Bullous Disorders in Pregnancy.
    Am J Clin Dermatol 2018 Feb 2. Epub 2018 Feb 2.
    Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.
    Autoimmune bullous diseases (AIBD), including pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid, and pemphigoid gestationis, pose significant therapeutic challenges, especially in pregnant and post-partum breastfeeding patients or those planning to conceive. Data on the safety and efficacy of therapeutic interventions during the perinatal period are lacking because randomized controlled trials are typically not performed in this setting. However, many of the treatments for AIBD are also used in other diseases, so data can be extrapolated from studies or case reports in these other patient populations. Read More

    Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Am J Clin Dermatol 2018 Jan 27. Epub 2018 Jan 27.
    AbbVie Inc., North Chicago, IL, USA.
    Background: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions.

    Objective: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and to investigate informative data from non-dermatologic indications.

    Methods: The safety of adalimumab 40-mg EOW versus EW dosing was examined during placebo-controlled and open-label study periods in patients with HS (three studies), psoriasis (two studies), Crohn's disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study). Read More

    Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
    Am J Clin Dermatol 2018 Jan 24. Epub 2018 Jan 24.
    Charité-Universitätsmedizin Berlin, Berlin, Germany.
    Background: The Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation.

    Objective: The aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values.

    Methods: Data came from the ASSURE-CSU study. Read More

    Understanding and Addressing Hair Disorders in Transgender Individuals.
    Am J Clin Dermatol 2018 Jan 19. Epub 2018 Jan 19.
    Department of Dermatology, The Permanente Medical Group, 975 Sereno Drive, Vallejo, CA, 94589, USA.
    In the United States, an increasing number of individuals are identifying as transgender. Males at birth who identify as females are called male-to-female (MTF) transgender individuals or trans women, and females at birth who identify as males are called female-to-male (FTM) transgender individuals or trans men. The transgender patient population possess unique health concerns disparate from those of the general populace. Read More

    The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis.
    Am J Clin Dermatol 2018 Jan 5. Epub 2018 Jan 5.
    Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St, Suite 1600, Chicago, IL, 60611, USA.
    Patients with atopic dermatitis (AD) have increased penetration of allergens, immune dysregulation (including shared cytokine pathways), and frequent use of emollients and topical medications, all of which may predispose toward developing allergic contact dermatitis (ACD). Recent systematic reviews have suggested that ACD is a significant clinical problem in both children and adults with AD. While this remains controversial, ACD remains an important comorbidity and potential exacerbant of AD in clinical practice. Read More

    A Review on Pityriasis Rubra Pilaris.
    Am J Clin Dermatol 2018 Jan 4. Epub 2018 Jan 4.
    National Skin Centre, 1 Mandalay Rd, Singapore, 308205, Republic of Singapore.
    Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. PRP can be subdivided into six clinical subtypes according to Griffiths' classification, based on age of onset, disease extent, prognosis, and other associated features. Read More

    Management of Itch in Atopic Dermatitis.
    Am J Clin Dermatol 2017 Dec 28. Epub 2017 Dec 28.
    Department of Dermatology and Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA.
    Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. Read More

    Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
    Am J Clin Dermatol 2017 Dec 19. Epub 2017 Dec 19.
    Dermatology Service, Memorial Sloan Kettering Cancer Center, 16 East 60th Street, New York, NY, 10022, USA.
    Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Read More

    Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Am J Clin Dermatol 2017 Dec 18. Epub 2017 Dec 18.
    Oncodermatology, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
    The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune related [immune-related adverse events (irAEs)], notably mediated by the triggering of cytotoxic CD4+/CD8+ T cell activation. Read More

    Granuloma Annulare: A Focused Review of Therapeutic Options.
    Am J Clin Dermatol 2017 Dec 11. Epub 2017 Dec 11.
    Dermatology Service, Veterans Affairs Medical Center, 800 Poly Place, Brooklyn, 11209, NY, USA.
    Granuloma annulare (GA) is a benign inflammatory disease associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and HIV infection. Common clinical subtypes include localized GA, generalized GA, subcutaneous GA, perforating GA, and patch GA. There exists an abundance of literature on GA, yet we know relatively little about its exact etiology and even less about its treatment. Read More

    Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment.
    Am J Clin Dermatol 2017 Dec 8. Epub 2017 Dec 8.
    Mount Sinai St. Luke's and West, 1090 Amsterdam Avenue, Suite 11B, New York, NY, 10025, USA.
    Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis that develops following cutaneous inflammation. Common causes of PIH include intrinsic skin conditions (e.g. Read More

    Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.
    Am J Clin Dermatol 2017 Dec 5. Epub 2017 Dec 5.
    Mount Sinai St. Luke's, 1090 Amsterdam Avenue, Suite 11B, New York, NY, 10025, USA.
    Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals. Read More

    Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
    Am J Clin Dermatol 2017 Nov 21. Epub 2017 Nov 21.
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
    Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor. Novel insights into both mutations driving tumorigenesis and immune escape mechanisms of these tumors have led to effective treatment options that have revolutionized the treatment of this disease. Targeting the MAPK kinase pathway (with BRAF and MEK inhibitors), as well as targeting checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed death 1 (PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities. Read More

    Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
    Am J Clin Dermatol 2017 Nov 2. Epub 2017 Nov 2.
    Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 4941492, Petah Tikva, Israel.
    Background: Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics.

    Objective: The aim of this study was to evaluate the efficacy and safety of biologic agents in AD. Read More

    Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Am J Clin Dermatol 2018 Feb;19(1):1-13
    Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, 1515 North Vermont Ave, 5th Floor, Los Angeles, CA, 90027, USA.
    An advanced understanding of the pathogenesis of psoriasis has led to the development of multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor inhibitors, ustekinumab, interleukin-17 inhibitors, and guselkumab (an interleukin-23 inhibitor recently approved for psoriasis) are commercially available biologic agents for psoriasis. Evidence from clinical trials provides pertinent information regarding the safety and efficacy of biologic agents for psoriasis, which should be integrated into clinical decision making. Read More

    Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
    Am J Clin Dermatol 2017 Dec;18(6):837-843
    Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
    Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Read More

    Vitamin D and the Skin: An Update for Dermatologists.
    Am J Clin Dermatol 2017 Oct 9. Epub 2017 Oct 9.
    Department of Dermatology, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France.
    Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Read More

    A Practical Guide About Tattooing in Patients with Chronic Skin Disorders and Other Medical Conditions.
    Am J Clin Dermatol 2017 Oct 9. Epub 2017 Oct 9.
    Department of Dermatology, AZ Sint-Jan Brugge-Oostende AV, 8000, Brugge, Belgium.
    With tattoos becoming increasingly mainstream, dermatologists are more and more often consulted by patients who are considering getting an ornamental, cosmetic, or even a medical tattoo, and who subsequently ask for advice. This includes not only patients with chronic skin diseases such as psoriasis or atopic dermatitis but also patients with other medical conditions. This review first explores the reasons why patients may want to get a tattoo and aims to offer some key information to dermatologists on what they should know about tattooing and the main risks associated with this procedure. Read More

    Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Am J Clin Dermatol 2017 Sep 18. Epub 2017 Sep 18.
    Dermatology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
    Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis. Read More

    Acne Scars: How Do We Grade Them?
    Am J Clin Dermatol 2017 Sep 11. Epub 2017 Sep 11.
    Department of Dermatology, University of California, Davis, 3301 C Street, Suite 1400, Sacramento, CA, 95816, USA.
    Acne vulgaris is a chronic inflammatory skin disease that can lead to permanent scarring. Although grading scales exist for acne scarring, there are many limitations, and there is still a need for a well validated gold standard scale for use in clinical practice or research trials. An objective measure of scar severity should be a component of global acne severity evaluations. Read More

    Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Am J Clin Dermatol 2017 Sep 8. Epub 2017 Sep 8.
    Department of Dermatology, University of Colorado School of Medicine, Mail Stop F703, 1665, North Aurora Court, Aurora, CO, 80045, USA.
    Basal cell carcinoma (BCC) is the most common type of skin cancer, with rising incidence rates primarily attributed to an aging population and ultraviolet radiation exposure. While the majority of BCCs are localized and respond to standard therapies, a very small minority of these tumors become locally destructive or metastasize. These advanced BCCs may not be amenable to localized treatment with surgery and/or radiation therapy. Read More

    Teledermatology: A Review and Update.
    Am J Clin Dermatol 2017 Sep 4. Epub 2017 Sep 4.
    Department of Dermatology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.
    Telemedicine is slowly transforming the way in which healthcare is delivered and has the potential to improve access to subspecialty expertise, reduce healthcare costs, and improve the overall quality of care. While many subspecialty fields within medicine today have either experimented with or begun to implement telemedicine platforms to enable remote consultation and care, dermatology is particularly suited for this care system as skin disorders are uniquely visible to the human eye. Through teledermatology, diagnostic images of skin disorders with accompanying clinical histories can be remotely reviewed by teledermatologists by any number of modalities, such as photographic clinical images or live video teleconferencing. Read More

    Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Am J Clin Dermatol 2017 Aug 31. Epub 2017 Aug 31.
    Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
    Melanoma is the most aggressive of the skin cancers, with historically high rates of morbidity and mortality due to its resistance to traditional cytotoxic therapies. Recently, however, breakthroughs in new therapies have dramatically changed clinical outcomes of this disease. These advances emerged from an improved understanding of tumor oncogenesis and the interacting tumor microenvironment. Read More

    Topical Corticosteroid Concerns Among Parents of Children with Psoriasis versus Atopic Dermatitis: A French Multicenter Cross-Sectional Study.
    Am J Clin Dermatol 2017 Aug 28. Epub 2017 Aug 28.
    Dermatology Department, University Hospital of Nancy, Batiment P Canton, 6 allée du Morvan, 54500, Vandoeuvre les Nancy, France.
    Background: Atopic dermatitis (AD) and psoriasis are chronic inflammatory cutaneous disorders for which the gold standard treatment is topical corticosteroids. Although fears about topical corticosteroids are known to be a primary cause of poor therapeutic adherence in AD, this has not been evaluated in psoriasis. TOPICOP is a helpful and easy-to-use tool for the evaluation of topical corticosteroid concerns (TCC). Read More

    Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment.
    Am J Clin Dermatol 2018 Feb;19(1):51-66
    Department of Medical Sciences, Dermatology, Uppsala University, Uppsala, Sweden.
    Hereditary ichthyoses are due to mutations on one or both alleles of more than 30 different genes, mainly expressed in the upper epidermis. Syndromic as well as nonsyndromic forms of ichthyosis exist. Irrespective of etiology, virtually all types of ichthyosis exhibit a defective epidermal barrier that constitutes the driving force for hyperkeratosis, skin scaling, and inflammation. Read More

    Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure.
    Am J Clin Dermatol 2018 Feb;19(1):119-126
    Rochester General Hospital Research Institute, 1425 Portland Avenue, Rochester, NY, 14621, USA.
    Background: Alopecia areata (AA) is an autoimmune disease characterized by non-scarring alopecia with T-cell infiltration at the affected hair follicle.

    Objective: Our aim was to study the potential link between hepatitis B virus (HBV) antigen exposure and AA.

    Methods: Two pediatric patients with AA following hepatitis B vaccination were identified in a general dermatology clinic. Read More

    Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature.
    Am J Clin Dermatol 2017 Aug 8. Epub 2017 Aug 8.
    Department of Dermatology and Cutaneous Surgery, University of Miami Hospital, 1475 NW 12th Ave. Suite 2175, Miami, FL, 33136, USA.
    Unwanted facial and body hair presents as a common finding in many patients, such as females with hirsutism. With advances in laser and light technology, a clinically significant reduction in hair can be achieved in patients with light skin. However, in patients with darker skin, Fitzpatrick skin types (FST) IV-VI, the higher melanin content of the skin interferes with the proposed mechanism of laser-induced selective photothermolysis, which is to target the melanin in the hair follicle to cause permanent destruction of hair bulge stem cells. Read More

    Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science.
    Am J Clin Dermatol 2018 Feb;19(1):103-117
    Department of Medicine, Dermatology Division, Arizona Cancer Center, University of Arizona, PO BOX 245024, 1515 N. Campbell Ave., Building #222, Levy Bldg., 1906E, Tucson, AZ, 85724-5024, USA.
    Natural plant oils are commonly used as topical therapy worldwide. They are usually easily accessible and are relatively inexpensive options for skin care. Many natural oils possess specific compounds with antimicrobial, antioxidant, anti-inflammatory, and anti-itch properties, making them attractive alternative and complementary treatments for xerotic and inflammatory dermatoses associated with skin-barrier disruption. Read More

    Birt-Hogg-Dubé Syndrome: A Review of Dermatological Manifestations and Other Symptoms.
    Am J Clin Dermatol 2018 Feb;19(1):87-101
    Department of Dermatology, University of California San Diego, 8899 University Center Lane, Suite 350, San Diego, CA, 92122, USA.
    Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant genodermatosis with malignant potential characterized by cutaneous and extracutaneous stigmata. Aberrations in the folliculin (FLCN) gene, which is located on chromosome 17, have been discovered in individuals with this condition. Over 150 unique mutations have been identified in BHD. Read More

    Cryotherapy for Intra- and Perianal High-Grade Squamous Intraepithelial Lesions in HIV-Positive Men who have Sex with Men.
    Am J Clin Dermatol 2018 Feb;19(1):127-132
    Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center, 1105 AZ, Amsterdam, The Netherlands.
    Background: Available treatment options for anal high-grade squamous intraepithelial lesions (HSIL) in HIV-positive men who have sex with men (MSM) are limited by low response rates and frequent recurrences. Cryotherapy is an established therapeutic option for several pre-malignant skin disorders.

    Methods: This retrospective, non-randomized study included HIV-positive MSM who received intra- and/or perianal HSIL cryotherapy treatment between 30 December 2008 and 23 April 2015. Read More

    Probiotics, Prebiotics, and Synbiotics for the Treatment and Prevention of Adult Dermatological Diseases.
    Am J Clin Dermatol 2017 Dec;18(6):721-732
    Department of Dermatology, UC Davis, 3301 C Street, Suite 1400, Sacramento, CA, 95816, USA.
    Background: Probiotic, prebiotic, and synbiotic supplementation is becoming more prevalent nowadays. Clinical studies have demonstrated some of the medical benefits of probiotics, prebiotics, and synbiotics within dermatology but an evidence-based review of their effects in adults is needed.

    Objective: The aim of this study was to identify evidence for the use of supplementation with probiotics, prebiotics, or synbiotics for the prevention and treatment of dermatological diseases in adults. Read More

    Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.
    Am J Clin Dermatol 2018 Feb;19(1):33-50
    Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
    Graft-versus-host disease (GVHD) is an immunological reaction and a frequent complication following allogeneic hematopoietic stem cell transplantation. It is associated with high mortality rates and may have a significant negative impact on the patient's quality of life, particularly in the chronic-stage setting. Many different organs can be involved, which leads to a wide range of clinical manifestations. Read More

    Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review.
    Am J Clin Dermatol 2018 Feb;19(1):79-86
    Department of Dermatology, University of California San Francisco, 1701 Divisadero Street, 3rd Floor, San Francisco, CA, 94115, USA.
    Rosacea fulminans is a rare inflammatory condition of the central face marked by the abrupt onset of erythematous coalescing papules, pustules, nodules, and draining sinuses. Due to infrequent reporting in the literature, the pathophysiology, classification, and nomenclature of this condition remain controversial. This comprehensive review evaluated a total of 135 cases of rosacea fulminans for clinical and histopathologic features and reported treatment strategies. Read More


    Drug-Induced Pyoderma Gangrenosum: A Review.
    Am J Clin Dermatol 2018 Feb;19(1):67-77
    York Dermatology Centre, Toronto, ON, Canada.
    Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that may be caused by an adverse drug reaction. We discuss the clinical presentation and outcomes of 52 cases of drug-induced PG reported to date in the literature. We conducted our literature search for case reports of drug-induced PG using keywords on PubMed and Medical Subject Heading (MeSH) terms on MEDLINE and EMBASE. Read More

    Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials.
    Am J Clin Dermatol 2018 Feb;19(1):15-22
    Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, 676 N. Saint Clair St, Suite 1600, Chicago, IL, 60611, USA.
    Background: Numerous diagnostic criteria for atopic dermatitis are used in clinical trials, which may limit comparison of results.

    Objective: We sought to determine the most commonly used atopic dermatitis diagnostic criteria in randomized controlled trials internationally.

    Methods: We performed a systematic review of randomized controlled trials with a pharmacological intervention from 2007 to 2016. Read More

    Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Am J Clin Dermatol 2018 Feb;19(1):23-32
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there are still unmet needs in the treatment of psoriasis, as current treatments are limited in terms of long-term efficacy, tolerability, safety, route of administration, and cost. Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3',5'-monophosphate, resulting in increased intracellular cyclic adenosine 3',5'-monophosphate levels in phosphodiesterase 4-expressing cells. Read More

    Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.
    Am J Clin Dermatol 2017 Dec;18(6):771-787
    Department of Dermatology, Division of Dermato-Immunology, KU Leuven, University Hospital Sint-Rafaël, Kapucijnenvoer 33, 3000, Leuven, Belgium.
    Approximately one in four patients treated with anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab, and golimumab) develops cutaneous adverse events, typically months to years after the initiation of treatment, with xerosis cutis, eczema (often psoriasiform), psoriasis, palmoplantar pustulosis, cutaneous infections, alopecia, and skin cancer being the most frequently encountered. The typical skin lesion of anti-tumor necrosis factor (TNF)-treated patients is orange-red psoriasiform eczema affecting the flexures, genitalia, scalp, or face, with high susceptibility to bacterial superinfection with Staphylococcus aureus. When adequate dermatological treatment is administered to patients with skin lesions receiving anti-TNF treatment, the discontinuation of anti-TNF agents is only rarely required. Read More

    Comment on: "Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study".
    Am J Clin Dermatol 2017 Oct;18(5):705-706
    Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), C/ Maestro Alonso s/n, 03010, Alicante, Spain.

    Vitiligo: An Update on Pathophysiology and Treatment Options.
    Am J Clin Dermatol 2017 Dec;18(6):733-744
    Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
    The pathophysiology of vitiligo is becoming increasingly clarified. In non-segmental vitiligo, early factors include activation of innate immunity, inflammasome activation, oxidative stress, and loss of melanocyte adhesion. Nonetheless, the main mechanism leading to non-segmental vitiligo involves an immune-mediated destruction of melanocytes. Read More

    Alopecia Areata of the Beard: A Review of the Literature.
    Am J Clin Dermatol 2017 Dec;18(6):789-796
    Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1475 NW 12th Ave., Miami, FL, 33136, USA.
    Alopecia areata (AA) is a T-cell mediated autoimmune disorder in which inflammatory cells attack the hair follicle, resulting in round, well-circumscribed patches of noncicatricial hair loss in normal appearing skin. AA affecting the beard area is well known and is referred to as AA of the beard (BAA) or AA barbae when involvement is limited exclusively to the beard. BAA has been documented in a select number of studies. Read More

    1 OF 21